ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
The review describes that GLP-1 receptor activation on these cells may inhibit their proliferation and differentiation, reduce their production of protective cytokines, and increase oxidative stress on neighboring fibroblasts
The direction is becoming clearer
This is a perfect complementary herb for L-tyrosine, as they are both effectively providing the same benefits in different ways
The test is available as a $99 add-on after your first month of treatment, offering data-driven clarity for long-term success